Johnson & Johnson has proposed a $5.5 billion settlement to resolve the vast majority of lawsuits alleging that its talc-based baby powder caused cancer — a bid to close out one of the longest-running legal sagas in corporate America.
Announced July 28, 2026, the proposal would cover roughly 69,000 claims consolidated in federal court in New Jersey, plus related state cases — about 99.75% of the remaining talc claims. The plaintiffs, largely women, allege that J&J's talc products were contaminated with asbestos and contributed to ovarian cancer.
The terms
The settlement is conditioned on at least 95% of remaining claimants agreeing to participate. Under the proposed schedule, J&J would make an initial payment of no more than $3 billion next year, with no further payments due until 2028.
The company's position
Crucially, J&J continues to deny that its talc products pose any cancer risk, framing the settlement as a way to end costly, distracting litigation rather than an admission. The company has fought these claims — the first filed in 2016 — through years of trials and two failed attempts to route the liability through bankruptcy.
Why it matters
Beyond the headline number, the deal signals a strategic reset: resolving legacy consumer-health liabilities lets J&J focus on its pharmaceutical and medtech businesses. For claimants, it offers a faster route to compensation than years more of litigation. The allegations remain contested, and the settlement still needs sufficient claimant buy-in to take effect.